RE: biotech sector - Thallion
Well does take a brain to figure that Thallion is high on the target list.
Shigamabs is a low risk high reward play ; first and only E.coli cure. E. Coli infection cost 700 Million to US health care system.
Approval of drug would mean sales of 400 per year for a major pharma - orphan status = no taxes for 7 years so similar impact on bottom line as if the drug was a 800M per year sales.
232 is the only compound able to kill cancer cells based on their Sugar eating ability.
4601 well that's the KRAS market.
Market is putting a negative to all this scientific assets.
C'mon!
Also, Caprion is growing at 40% per year.
Value is definitively here.
Just a matter of time before we get a hostile take over.
Well, for now the next catalysts are the following:
4601 positive preliminary test results.
Arbitration win on 232
Shigamabs partnership deal.
3 catalyst in coming weeks.
3 roll of the dice to get rich.
Won't surprise me if all 3 happens, won't surprise me if we get 15$ per share.